Glibenclamide—10-h Treatment Window in a Clinically Relevant Model of Stroke

Glibenclamide improves outcomes in rat models of stroke, with treatment as late as 6 h after onset of ischemia shown to be beneficial. Because the molecular target of glibenclamide, the sulfonylurea receptor 1 (Sur1)-regulated NC(Ca-ATP) channel, is upregulated de novo by a complex transcriptional m...

Descripción completa

Detalles Bibliográficos
Autores principales: Simard, J. Marc, Woo, Seung Kyoon, Tsymbalyuk, Natalia, Voloshyn, Oksana, Yurovsky, Vladimir, Ivanova, Svetlana, Lee, Ryan, Gerzanich, Volodymyr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362710/
https://www.ncbi.nlm.nih.gov/pubmed/22707989
http://dx.doi.org/10.1007/s12975-012-0149-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362710/
https://www.ncbi.nlm.nih.gov/pubmed/22707989
http://dx.doi.org/10.1007/s12975-012-0149-x

Ejemplares similares